Nathan Weinstein
Stock Analyst at Aegis Capital
(0.27)
# 4,163
Out of 4,876 analysts
61
Total ratings
13.33%
Success rate
-26.12%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.30 | +6,053.85% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.70 | +2,042.86% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.84 | +616.25% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.70 | +4,900.00% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.29 | +162.01% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.15 | +1,295.35% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $5.62 | +77.94% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $19.28 | +154.15% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.24 | +11,996.77% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $4.05 | +53,233.33% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.17 | +2,464.10% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.85 | +1,076.47% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $49.45 | +223.56% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $27.49 | +103.71% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $2.20 | +1,127.27% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.69 | +4,962.92% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.98 | +506.09% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $8.99 | +734.26% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $3.10 | +2,738.71% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $1.97 | +9,037.06% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $3.35 | +3,929.85% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $6.50 | +115.38% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $15.71 | +1,300.38% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $3.22 | +163.98% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.30
Upside: +6,053.85%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.70
Upside: +2,042.86%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.84
Upside: +616.25%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.70
Upside: +4,900.00%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.15
Upside: +1,295.35%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $5.62
Upside: +77.94%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $19.28
Upside: +154.15%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.24
Upside: +11,996.77%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $4.05
Upside: +53,233.33%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $1.17
Upside: +2,464.10%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.85
Upside: +1,076.47%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $49.45
Upside: +223.56%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $27.49
Upside: +103.71%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $2.20
Upside: +1,127.27%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.69
Upside: +4,962.92%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $1.98
Upside: +506.09%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $8.99
Upside: +734.26%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $3.10
Upside: +2,738.71%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $1.97
Upside: +9,037.06%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $3.35
Upside: +3,929.85%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $6.50
Upside: +115.38%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $15.71
Upside: +1,300.38%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $3.22
Upside: +163.98%